Drug Database
Back to search

United States· US:57894-514_e037897a-b42a-413f-8f3f-c0f5ee7b5125

Rybrevant Faspro

A other monoclonal antibodies and antibody drug conjugates product containing amivantamab and hyaluronidase-lpuj (human recombinant), registered in United States by Janssen Biotech, Inc.. The same ATC class is registered in 5 of our 19 countries.

ATC L01FXUS label

Checked against FDA National Drug Code directory (United States) on

Informational only — not a medical device.

SOURCE REGISTER · USFDA National Drug Code directory (Unite…normalisedRybrevant FasproATCL01FXREGISTER NO.US:57894-514_e037897a…PACKS LISTED1CHECKEDJune 3, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about amivantamab and hyaluronidase-lpuj (human recombinant)Answers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Amivantamab and hyaluronidase-lpuj (human recombinant) is registered in 5 of 19 countries.

Countries holding a registration under ATC L01FX (other monoclonal antibodies and antibody drug conjugates), each read from that country’s own register.

  • This record: United States, from FDA National Drug Code directory (United States)
  • 4 of them publish a price we can compare per daily dose
Search amivantamab and hyaluronidase-lpuj (human recombinant) products by name

Amivantamab and hyaluronidase-lpuj (human recombinant) · ATC L01FX

5 / 19 countries

  • Finlandprice
  • Icelandprice
  • Netherlands
  • Polandprice
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FDA National Drug Code directory (United States)
Active substance
AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT)
Manufacturer
Janssen Biotech, Inc.
Country
United States (US)
ATC code
L01FX
ATC class
Other monoclonal antibodies and antibody drug conjugates
Reimbursed
Not published by this register
Source register
FDA National Drug Code directory (United States)
Last checked
June 3, 2026

Packs & prices · 1

  • ndc11
    5789451401
    1 VIAL, SINGLE-DOSE in 1 CARTON (57894-514-01) / 14 mL in 1 VIAL, SINGLE-DOSE

Regulatory notes

UNII (FDA substance ID)
0JSR7Z0NB6
AMIVANTAMAB
RxCUI 2549199
DailyMed SPL labels
1 version tracked

Same class

Other records under L01FX

Other monoclonal antibodies and antibody drug conjugates, as other registers publish it.

All amivantamab and hyaluronidase-lpuj (human recombinant) products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/f549f8d9-9cd9-4862-8168-6ecd475bc5bc
GET /v1/drugs/f549f8d9-9cd9-4862-8168-6ecd475bc5bc?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unii": {
    "unii": "0JSR7Z0NB6",
    "rxcui": "2549199",
    "inchikey": null,
    "display_name": "AMIVANTAMAB",
    "substance_type": "protein",
    "ingredient_type": "INGREDIENT SUBSTANCE"
  },
  "route": "SUBCUTANEOUS",
  "spl_meta": {
    "1466c070-9f97-4fa4-a955-6a6b59981fb8": {
      "match": "brand_token",
      "title": "RYBREVANT (AMIVANTAMAB-VMJW) INJECTION [JANSSEN BIOTECH, INC.]",
      "spl_version": "16",
      "published_date": "2026-03-18"
    }
  },
  "productid": "57894-514_e037897a-b42a-413f-8f3f-c0f5ee7b5125",
  "productndc": "57894-514",
  "dosage_form": "INJECTION",
  "dea_schedule": null,
  "product_type": "HUMAN PRESCRIPTION DRUG",
  "substance_name": "AMIVANTAMAB; HYALURONIDASE (HUMAN RECOMBINANT)",
  "proprietary_name": "Rybrevant Faspro",
  "active_ingred_unit": "mg/14mL; mg/14mL",
  "application_number": "BLA761433",
  "marketing_category": "BLA",
  "nonproprietary_name": "AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT)",
  "start_marketing_date": "20251219",
  "active_numerator_strength": "2240; 28000"
}
API referenceMCP serverPlans

See everything about amivantamab and hyaluronidase-lpuj (human recombinant).

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console